OncoMatch/Clinical Trials/NCT06622941

Study to ONO-4538 in Patients With Rhabdoid Tumor

Is NCT06622941 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ONO-4538 for rhabdoid tumor.

Phase 2RecruitingOno Pharmaceutical Co. LtdNCT06622941Data as of Jun 2026Location: Japan

Treatment: ONO-4538 — Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

Extracted eligibility criteria

Treatments studied

Other

ONO-4538

Demographics

Ages ≥ 1

Prior therapy

Min 1 prior line

Must have received: chemotherapy — for rhabdoid Tumors

Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Is NCT06622941 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received chemotherapy.

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.